retatrutide triple agonist glp-1 gip glucagon phase 2 results Retatrutide: The Next Generation of Weight Loss Medication? What is the pipeline for

We had to do a bit of digging to find the answer to this one

When your body produces too many cytokines you end up with chronic inflammatory diseases

This oxidative stress plays a central role in disease progression from simple steatosis to more serious conditions such as non-alcoholic steatohepatitis (NASH), fibrosis, and potentially cirrhosis

Furthermore, GSTP1-1 has also been shown to bind and inhibit tumor necrosis factor receptor-associated factor 2 (TRAF2), an upstream activator of JNK, thus blocking the MAPK/JNK signaling cascade at multiple levels 29

Generally, the oral dosage ranges from 500 mg to 2000 mg per day, while intravenous (IV) administration may involve higher doses